Molecular genetics of the NCLs — status and perspectives  by Siintola, Eija et al.
Biochimica et Biophysica Acta 1762 (2006) 857–864
www.elsevier.com/locate/bbadisReview
Molecular genetics of the NCLs — status and perspectives
Eija Siintola a,⁎, Anna-Elina Lehesjoki a, Sara E Mole b
a Folkhälsan Institute of Genetics, Department of Medical Genetics and Neuroscience Center, Biomedicum Helsinki, University of Helsinki, Finland
b MRC Laboratory for Molecular Cell Biology and Departments of Paediatrics & Child Health and Biology, University College London, UK
Received 5 April 2006; accepted 23 May 2006
Available online 27 May 2006Abstract
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurodegenerative disorders characterized by the accumulation of autofluo-
rescent storage material in many cell types, including neurons. Most NCL subtypes are inherited in an autosomal recessive manner and characterized
clinically by epileptic seizures, progressive psychomotor decline, visual failure, variable age of onset, and premature death. To date, seven genes
underlying human NCLs have been identified. Most of the mutations in these genes are associated with specific disease subtypes, while some result in
variable disease onset, severity and progression. In addition to these, there are still disease subgroups with unknown molecular genetic backgrounds.
Although apparent clinical homogeneity exists within some of these subgroups, actual genetic heterogeneity may complicate gene identification.
Additional clues to the identification of these unknowngenesmay come from animalmodels of NCL and from functional studies of already knowngenes
which may suggest further candidates.
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The neuronal ceroid lipofuscinoses (NCLs) are the most
common inherited neurodegenerative disorders of childhood.
They are pathologically characterized by the accumulation of
autofluorescent storage material in many cell types including
neurons [1]. The age of onset ranges from infancy to adulthood.
The childhood forms are autosomal recessively inherited and
are characterized by epileptic seizures, progressive psychomo-
tor decline, visual failure, variable age of onset, and premature
death, while the rare adult forms are inherited in both autosomal
dominant and recessive manners, with the main clinical
symptom being dementia [2]. Estimates of incidence range
from 1 in 12,500 to 1 in 100,000 [1,3] making the NCLs rare
disorders that nevertheless have a devastating impact on the
affected families with concomitant burdens placed on health
and support services over many years.⁎ Corresponding author. Folkhälsan Institute of Genetics, Biomedicum
Helsinki, P.O. Box 63 (Haartmaninkatu 8), 00014 University of Helsinki,
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doi:10.1016/j.bbadis.2006.05.006In the 1960s–1980s, the NCLs were divided into four
subtypes according to the age of onset, the clinical picture and
the ultrastructure of the storage material. These subtypes were:
infantile neuronal ceroid lipofuscinosis (INCL), late-infantile
neuronal ceroid lipofuscinosis (LINCL), juvenile neuronal
ceroid lipofuscinosis (JNCL), and adult neuronal ceroid
lipofuscinosis (ANCL). More recently variants of these
subtypes, especially of the late-infantile subtype, have been
characterized.
The first clinical description of the NCLs was published in
1826 [4] followed by several others around the turn of the 19th
century [5–7], but the chromosomal localization of the first
gene underlying a subtype of the NCLs was discovered only in
1989 [8] and the first genes were identified in 1995 [9,10].
During the last decade, a total of seven genes underlying the
human NCLs (CLN1, CLN2, CLN3, CLN5, CLN6, CLN8, and
CTSD) have been identified [9–17]. The methods used in the
cloning of these genes included positional cloning and
homozygosity mapping and, after the identification of the
disease loci, narrowing them by utilizing the founder effects in
different populations. However, in one case (CLN2) a
biochemical approach revealed the identity of the gene [11],
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applied [16,17]. Most of the mutations in individual NCL genes
are associated with certain disease subtypes with characteristic
clinical features and a specific age of onset, but some also result
in a variable disease onset or a more protracted disease
progression, and in one case (Northern epilepsy caused by
mutations in CLN8) in a disorder that was not initially
recognized as NCL [18].
While seven NCL genes have been cloned, there are clearly
still more to be identified. At least three putative genes (CLN4,
CLN7, and CLN9) exist, but additional ones can also be anti-
cipated. Nowadays, with the availability of the human genomic
sequence and the possibility to rapidly screen thousands of
genomic markers in a single experiment (e.g., single nucleotide
polymorphism, SNP, arrays), gene cloning is considerably
easier. However, NCL gene identification is challenging
because of the likely genetic heterogeneity within phenotypi-
cally similar NCL subgroups. Consanguineous families there-
fore remain ideal for identification of these new genes, but the
limited availability of such families for study currently limits
this approach.
2. Known human NCL genes and their defects
2.1. CLN1
The CLN1 gene was first localized by linkage analysis to
chromosome 1p32 [19] and eventually identified by positional
cloning as a gene encoding the palmitoyl protein thioesterase 1
(PPT1) enzyme [10]. In vitro, PPT1 removes palmitate groups
from S-acylated proteins [20]. In non-neuronal cells PPT1 is a
soluble lysosomal protein that is targeted to lysosomes through
the mannose-6-phosphate pathway [21,22]. In neuronal cells
PPT1 is localized to synaptosomes and synaptic vesicles [23,24]
and it is preferentially targeted to axons and specifically to
axonal varicosities and presynaptic terminals [25]. CLN1 is
conserved down to yeast, an orthologue exists in Schizosac-
charomyces pombe but surprisingly not in Saccharomyces
cerevisiae, suggesting that it performs a basic and essential
cellular function, consistent with the early disease onset [26,27].
The majority of the mutations identified in the CLN1 gene
cause NCL with onset in infancy (INCL). Early development of
children with INCL is normal until the age of 6–18 months
when decreased head growth and retardation of psychomotorTable 1
Genotype–phenotype correlations of currently known human NCL genes
Gene No. of mutations Widespread, common mu
CLN1/PPT1 42 2
CLN2/TPPI 53 2
CLN3 40 1
CLN5 5 None
CLN6 25 None
CLN8 10 None
CTSD 3 Nonedevelopment become apparent [28,29]. Other clinical features
include epileptic seizures, muscular hypotonia, ataxia, and
visual failure. The disorder leads to very severe brain atrophy,
and the patients lose the ability to walk by the age of 3 years,
and die at the age of 6–15 years. In addition to INCL, mutations
in the CLN1 gene cause NCL forms with later onset and
protracted progression: the late-infantile, juvenile and adult
onset variants [30–32] (Table 1). However, all NCL forms with
mutations in CLN1 are associated with granular storage material
in the cells, where the main components of accumulated protein
are the sphingolipid activator proteins (SAPs) A and D [33,34].
In addition, mutations in CLN1, irrespective of their associated
severity, cause decreased enzyme activity that can be readily
detected diagnostically [32,35–37].
To date, over 40 disease-causing mutations have been
described in the CLN1 gene (NCLMutation Database,www.ucl.
ac.uk/ncl/mutation). They are distributed throughout the gene.
The most common mutation (c.364A>T) is associated with a
founder effect in the Finnish population and causes onset in
infancy [10]. It results in a p.Arg122Trp change causing a defect
in the transport of the gene product from the endoplasmic
reticulum (ER) to lysosomes [10,21]. Other common CLN1
mutations occur in several different populations worldwide,
including two found in individuals of Scottish and Irish origin
(c.29T>A, p.Leu10X; c.223A>C, p.Thr75Pro), as well as one
that is more widely distributed (c. 451C>T, p.Arg151X). The
crystal structure of the PPT1 protein allows the analysis of
genotype–phenotype correlations [38]. Missense mutations that
cluster near the active site of the enzyme generally cause severe
clinical phenotypes. In contrast, mutations that make missense
changes in more peripheral sites lead to less severe phenotypes
[39].
2.2. CLN2
The CLN2 locus was localized to chromosome 11p15 by the
homozygosity mapping strategy [40]. The gene, encoding the
lysosomal enzyme tripeptidyl peptidase (TPP1), was identified
using a functional assay to identify the mannose-phosphorylat-
ed protein that was missing in brain samples from patients with
classical LINCL (cLINCL) [11]. TPP1 is a pepstatin-insensitive
protease that cleaves tripeptides from the amino-termini of poly-
peptides undergoing degradation [41]. Subunit c of mitochondrial
ATP synthase, the major protein component of the storage material,tations Genotype–phenotype correlation
Infantile (∼ 50%), late-infantile, juvenile, adult
Late-infantile, juvenile and protracted
Common mutation: juvenile onset,
others may be associated with later onset or protracted
Late-infantile, juvenile and protracted
Late-infantile with little variation
Finnish mutations: juvenile onset and protracted (EPMR)
other mutations: late-infantile with little variation
Congenital and late-infantile
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part of a gene family, with members even in bacterial species [11].
However no clear functional homologues occur in simple model
organisms such as the yeasts S. pombe or S. cerevisiae, unlike some
of the otherNCLgenes (PorterM. andMole S.E., unpublished data).
The majority of mutations in the CLN2 gene cause cLINCL,
where the first symptoms are generally observed at the age of 2–
4 years [45]. The clinical features include seizures, ataxia,
myoclonus, developmental and mental retardation, visual
failure, and speech impairment. Death usually occurs in mid
childhood. A few of the mutations cause a more protracted or
juvenile onset form of NCL [46–48] (Table 1).
Over 50 different disease-causing mutations have now been
identified in the CLN2 gene (NCLMutation Database,www.ucl.
ac.uk/ncl/mutation). Two of these are more common than the
others: IVS5-1G>C affects the splicing of the transcript, and
c.622C>T creates a stop codon at position 208 (p.Arg208X).
One mutation (c.851G>T, p.Gly284Val) may be particularly
predominant in Canada suggesting a possible founder effect
[49].
2.3. CLN3
CLN3 was localized to chromosome 16 by demonstration of
linkage to the haptoglobin locus [8], and after refined mapping,
to 16p12 [50]. Finally, it was identified by a positional cloning
strategy as a gene encoding a lysosomal transmembrane protein
[9,51,52] that in neurons also localizes to neuronal synapses but
not to synaptic vesicles [53]. The function of CLN3 is still
unclear but it is evolutionary conserved down to yeast which
suggests an important function in eukaryotic cells [54–57].
Mutations in the CLN3 gene cause NCL with juvenile onset
(JNCL), and occasionally disease of slower progression. JNCL,
the most frequent subtype of the NCLs, is clinically charac-
terized by an age of onset of 4–7 years, with progressive visual
failure leading to blindness always occurring before other
symptoms [58]. Seizures and psychomotor deterioration follow,
with death occurring in the second or third decade of life.
Uniquely for the NCLs, JNCL caused by mutations in CLN3 is
always associated with vacuolated lymphocytes [58].
At least 40 mutations are currently known in the CLN3 gene
(NCLMutation Database, www.ucl.ac.uk/ncl/mutation). The most
common of these is a 1-kb deletion (c.461–677del) resulting in a
frameshift after the cysteine residue at position 153 and premature
termination [9]. It occurs world-wide but notably in European and
North American populations. In non-neuronal cells the mutation
leads to a defect in the intracellular transport of the mutant protein
from the ER to the lysosomes and in neurons from the cell soma to
the extensions [52]. This mutation is so predominant that most
patients are homozygous or at least heterozygous for it. Avariety of
other mutations exist, some of which are associated with a later
onset or a more protracted disease course (Table 1).
2.4. CLN5
The CLN5 gene was localized to chromosome 13q22 by a
genome-wide scan and later identified by a positional cloningstrategy [12,59]. It encodes a lysosomal glycoprotein with no
homology to other known proteins [12,60]. The CLN5 protein
is synthesized as four distinct forms of different lengths that are
translated using alternative initiator methionines [61]. The
longest of these forms has been shown to be associated with the
lysosomal membrane while the others are thought to be soluble
proteins [61]. The function of CLN5 is currently unknown. The
CLN5 gene is conserved in vertebrates, but homologues are not
readily identifiable in invertebrates (Porter M. and Mole S.E.,
unpublished data).
The NCL subtype with mutations in the CLN5 gene was
originally described in the Finnish population and is often referred
to as Finnish variant late-infantile NCL (vLINCLFin) [62]. It is
clinically similar to the classical form of LINCL except for a later
age of onset that lies between 5 and 7 years.
Five different disease-causing mutations in CLN5 have been
described (NCLMutationDatabase,www.ucl.ac.uk/ncl/mutation).
The most common of these, c.1175delAT (p.Tyr392X), present
only in the Finnish population, blocks lysosomal targeting of
the mutant protein [60]. Most NCL patients carrying CLN5
mutations are of Finnish or Swedish origin with the exception
of one family originating from The Netherlands and one from
Columbia. The latter shows a later age of onset, in the juvenile
range, with visual failure as a leading symptom [63] (Table 1).
NCL patients with later ages of onset should thus be considered
for mutations in CLN5.
Recently, a naturally occurringmutation (c.619C>T, p.Gln206X)
causing an NCL phenotype in Border collie dogs was described in
the Cln5 gene [64].
2.5. CLN6
The CLN6 gene was localized to chromosome 15q21–23 by
homozygosity mapping [40] and identified by positional cloning
[14,15]. The CLN6 protein is a novel transmembrane protein that
localizes to the ER [65,66]. It has no homology with known
proteins and is highly conserved across vertebrates [15]. The
function of the protein is currently unknown.
Most mutations in the CLN6 gene cause a variant of late-
infantile onset NCL (vLINCL) that clinically resembles
classical LINCL, though the age of onset is somewhat later,
between 4 and 5 years of age [67].
To date, 25 disease-causing mutations have been identified
in the CLN6 gene (NCL Mutation Database, www.ucl.ac.uk/
ncl/mutation). The most common of these is a nonsense
mutation c.214G>T (p.Glu72X) present in patients of Costa
Rican origin. In addition to these, patients with CLN6
mutations originate mostly from Europe (the Mediterranean
and eastern regions), and the Indian subcontinent [68,69]. A
few mutations occur at increased frequency in families from
Pakistan and Portugal. Two homozygous mutations have been
identified in two families of Turkish origin [70]. A group of
patients of Roma Gypsy origin are associated with two
different haplotypes at the CLN6 locus, but no mutations have
yet been described [68,69]. One compound heterozygote
patient with p.Tyr221Ser and an unknown mutation shows a
more protracted course of the disease, but the other mutations
860 E. Siintola et al. / Biochimica et Biophysica Acta 1762 (2006) 857–864are associated with indistinguishable clinical features [68]
(Table 1).
A naturally occurring frameshift mutation (c.307insC) in the
Cln6 gene underlies the NCL phenotype in mouse (nclf)
[14,15]. CLN6 is also predicted to be orthologous to the gene
causing NCL phenotype in South Hampshire and Merino sheep
[71,72].
2.6. CLN8
The CLN8 gene was localized to the short arm of
chromosome 8 by linkage analysis [73] and later identified
by the positional cloning method [13]. The function of the
CLN8 protein is unknown but it is predicted to be a
transmembrane protein with several membrane spanning
domains [13]. In non-neuronal cells CLN8 is localized to the
ER and partially to the ER–Golgi intermediate compartment
[74]. In neurons, CLN8 is localized to the ER, but an additional
location outside the ER has been suggested in polarized cells
[75]. CLN8 has recently been connected to the TRAM-Lag1p-
CLN8 (TLC) superfamily of proteins suggested to have a role
in biosynthesis, metabolism, and sensing of lipids [76]. CLN8,
like the other known genes causing vLINCL, CLN5 and CLN6,
appears to be confined to vertebrate species (Porter M. and
Mole S.E., unpublished data).
CLN8 was first identified as a causative gene for Northern
epilepsy (also known as progressive epilepsy with mental retar-
dation, EPMR) in Finnish patients [13]. Later, identification of
intraneuronal storage material, characteristic to NCL, linked
EPMR to this disease group [77]. The first symptoms in EPMR
patients, epileptic seizures, are observed at the age of 5–10
years [18]. Two to 5 years after disease onset, the patients begin
to show progressive mental deterioration, and motor and
behavioral problems. It is now clear that EPMR is a mutation-
specific phenotype, as mutations in CLN8 were recently
described in patients with a phenotype of variant late-infantile
NCL [78,79] (Table 1). Such mutations have now been found in
patients of Turkish and Italian origin [78,79] suggesting that
patients of other ethnic origins with a similar phenotype may
also have mutations in CLN8.
To date, ten mutations have been identified in the CLN8 gene
(NCL Mutation Database, www.ucl.ac.uk/ncl/mutation and
Siintola, E. and Lehesjoki, A.-E., unpublished data). The most
common of these mutations is c.70C>G (p.Arg24Gly)
underlying the EPMR phenotype [13]. This mutation in
compound heterozygous form with another missense mutation
(c.709G>A, p.Gly237Arg) in a Finnish patient results in an
even more protracted clinical course of EPMR (Siintola, E. and
Lehesjoki, A.-E., unpublished data). In contrast, eight of the
mutations result in the more severe vLINCL phenotype in
Turkish and Italian patients [78,79].
A frameshift mutation (c.267–268insC) in the Cln8 gene
underlies the phenotype of the motor neuron degeneration
(mnd) mouse that is a naturally occurring mouse model for NCL
[13]. In addition, a mutation (c.491T>C, p.Leu164Pro) in the
Cln8 gene has been shown to cause an NCL phenotype in
English Setter dogs [80].2.7. CTSD
As mutations in the Cathepsin D (Ctsd) gene had been
observed in two naturally occurring animal models for NCL
[81,82], CTSD was a candidate for human NCL. Recently, it
was recognized as the causative gene for two separate human
NCL phenotypes [16,17] (Table 1). CTSD is a lysosomal
aspartic protease that belongs to the pepsin family [83,84] and is
conserved at least down to Drosophila melanogaster and
Caenorhabditis elegans [82,85].
A homozygous duplication (c.764dupA) that creates a pre-
mature stop codon at position 255 (p.Tyr255X) results in congenital
NCL with absence of CTSD immunostaining in brain [16].
Congenital NCL is the earliest-onset and most aggressive form of
human NCLs that presents clinically with extreme brain atrophy,
microcephaly and epilepsy at birth, with death occurring within
hours to weeks [86]. Compound heterozygosity for two CTSD
missense mutations (g.6517T>A, p.Phe229Ile; g.10267G>C, p.
Trp383Cys), with resulting CTSD deficiency, on the other hand,
was shown to underlie an NCL-like neurodegenerative phenotype
with blindness and psychomotor disability manifesting at early-
school age [17].
An active sitemutation (corresponding to human p.Asp295Asn)
in the ovine Ctsd gene causes congenital NCL in sheep [81], while
a missense mutation (c.597G>A, p.Met199Ile) in canine Ctsd is a
cause of a late-onset NCL in American Bulldogs [82].
3. Unknown human genes causing NCL
In addition to the seven known genes underlying human
NCLs, three putative genes (CLN4, CLN7, and CLN9) exist and
an undefined number of other NCL genes are likely to exist. If
enough patients and families for a single clinical phenotype
exist, positional cloning following a genome-wide scan may be
applied to identify the gene. Alternatively, a candidate gene
approach could be undertaken. Candidate genes may emerge
from functional studies of already known genes, e.g., through
mRNA and proteomic profiling and from animal models of
NCL. For example, deficiencies in cathepsin F (Ctsf), ClC-3
(Clcn3), and ClC-7 (Clcn7) lead to NCL-like phenotypes in
animals [87–90], rendering the corresponding human genes
good candidates for novel NCL genes. The genes underlying
more than four different dog models should also provide good
candidates once these have been identified.
3.1. CLN4
The adult onset form of NCLs (ANCL) is the mildest NCL
subtype consisting of a heterogeneous group of disorders that
includes at least two subtypes [91,92]. The age of onset is
approximately 30 years, varying between 10 and 50 years, and
the death occurs about 10 years after the onset [91]. The main
clinical symptom is dementia, and the other clinical features
depend on the subtype and include progressive myoclonus
epilepsy, ataxia, late pyramidal and extra-pyramidal features,
behavioral changes and motor disturbances [91,92]. Both domi-
nant and recessive forms of ANCL have been reported. Given
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genetically very heterogeneous.
The CLN4 gene or genes underlying adult NCL have not yet
been identified. As mutations in several NCL genes result in
variable ages of onset, including adult onset associated with
CLN1 mutations [32], other NCL genes could be considered
candidates for ANCL in addition to novel, yet unidentified
genes. A new mouse model for NCL deficient in cathepsin F
suggests this gene as a candidate for adult onset NCL [90].
However, analysis of adult onset patients did not reveal any
mutations [90].
3.2. CLN7
A variant form of LINCL present in Turkish patients (vLI
NCLTurk) was originally considered a distinct clinical and
genetic entity (CLN7) [93]. The clinical presentation in these
patients is similar to other forms of vLINCL including a later
onset of the disease than for classical LINCL, seizures, psycho-
motor decline, myoclonus, and loss of vision [94,95].
Recently, mutations in the CLN6 and CLN8 genes have been
shown to underlie a subset of vLINCLTurk [70,78]. The remai-
ning subgroup of patients with no underlying gene identified
may represent a novel gene (CLN7) or genes since the influence
of other human NCL genes and genes underlying the NCL-like
phenotypes in animals (CLCN3 and CLCN7) have been ex-
cluded by homozygosity analysis on the respective loci [70].
Moreover, the genetic background of this phenotype is most
likely heterogeneous despite the apparent homogeneity of the
clinical phenotypes (Siintola, E. and Lehesjoki, A.-E., unpub-
lished data).
3.3. CLN9
The most recently reported subtype of NCLs is referred to as
CLN9-deficient. It was described in two Serbian sisters and two
German brothers [96] and has clinical features that are quite
similar to JNCL but is distinguished from it by gene expression
profiles and a distinct phenotype of CLN9-deficient cells [96].
The genetic basis of this variant has not yet been resolved but
the involvement of the other human NCL genes was ruled out
by enzymatic assays and/or sequencing of the coding regions
[96], as well as functionally by transfection of the NCL genes
into the CLN9-deficient cells and screening for rescue of the
phenotype [97]. Based on various functional assays, CLN9 is
proposed to be a regulator of dihydroceramide synthase [97]
suggesting a possible link with the as yet unknown function of
CLN8. Current attempts at homozygosity mapping of a
consanguineous family may lead to identification of the gene
locus (Boustany, R.-M., personal communication).
4. Conclusions and future perspectives
The molecular genetics of the NCLs has turned out to be
more complicated than envisioned when the first four gene
symbols (CLN1–4) were assigned in the 1990s. It is still unclear
whether the function of all NCL genes is linked or whether themarker phenotype of autofluorescent storage material in asso-
ciation with neurodegeneration caused by unrelated biological
events remains the common element. Functional analysis of the
known genes, identification of novel disease-causing genes in
humans and in animal models and analysis of experimental
models with NCL-like disease should eventually provide the
complete genetic picture for the NCLs.
5. Note added in proof
Mutations in the orthologues of two human NCL genes have
recently been found to cause NCL in large animals: A mutation
in the sheep gene CLN6 causes NCL in Merino sheep, and the
same gene has reduced expression on the South Hampshire
sheep with NCL (Tammen et al., this issue). A mutation in the
cow gene CLN5 causes NCL in Devon cattle (Houweling et al.,
this issue).
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